Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA4 | P22748 | 2/20 | 0.42 |
| ▸ | CA6 | P23280 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29547008 | 1.00 | LMNA (0.55) | LMNARAB9AMAPK1HTTTSHR | |
| SCHEMBL4037801 | 0.84 | LMNA (0.50) | LMNARAB9AMAPK1HTTTSHR | |
| SCHEMBL31224923 | 0.84 | LMNA (0.50) | LMNARAB9AMAPK1HTTTSHR | |
| SCHEMBL3502920 | 0.84 | ALDH1A1 (0.42) | LMNARAB9AMAPTL3MBTL1CES2 | |
| SCHEMBL10195681 | 0.82 | PARP1 (0.50) | TSHRCA1CA2KDM4ECES2 | |
| SCHEMBL29954222 | 0.82 | PARP1 (0.50) | TSHRCA1CA2KDM4ECES2 | |
| SCHEMBL362782 | 0.79 | CA1 (0.50) | LMNARAB9AMAPK1HTTTP53 | |
| SCHEMBL12813483 | 0.79 | ERN1 (0.47) | POLBCES2CES1SMN1; SMN2ALDH1A1 | |
| SCHEMBL20995554 | 0.79 | HDAC6 (0.46) | HTTTSHRCA2GAASMN1; SMN2 | |
| SCHEMBL29956912 | 0.79 | ERN1 (0.47) | POLBCES2CES1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117679560-A | Bone defect repair porous scaffold loaded with black phosphorus active oxygen elimination and slow release drugs and preparation method thereof | 浙江大学绍兴研究院 | 2024-03-12 | — | — | CN | claimed |
| CN-113634240-B | Fluorescent magnetic composite nanofiber, preparation method and application thereof | 宏葵生物（中国）股份有限公司 | 2023-10-27 | — | — | CN | claimed |
| CN-116712599-A | High-tensile wound-healing-promoting antibacterial hydrogel dressing, preparation method and application | 江南大学附属医院 | 2023-09-08 | — | — | CN | claimed |
| CN-113697808-B | Transition metal oxide-loaded porous carbon material, and preparation method and application thereof | 山东交通学院 | 2022-11-18 | — | — | CN | claimed |
| CN-111424429-B | Metal sulfide porous framework material, and preparation method and application thereof | 山东交通学院 | 2022-09-23 | — | — | CN | claimed |
| CN-113697808-A | Transition metal oxide-loaded porous carbon material, and preparation method and application thereof | 山东交通学院 | 2021-11-26 | — | — | CN | claimed |
| CN-113634240-A | Fluorescent magnetic composite nanofiber, and preparation method and application thereof | 山东交通学院 | 2021-11-12 | — | — | CN | claimed |
| CN-111424429-A | Metal sulfide porous framework material, and preparation method and application thereof | 山东交通学院 | 2020-07-17 | — | — | CN | claimed |
| US-12624028-B2 | 1H-pyrazolo[4,3-G]isoquinoline and 1H-pyrazolo[4,3-g]quinoline derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260109708-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS DEGRADERS OF MK2 KINASE | CELGENE CORP (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4661875-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS DEGRADERS OF MK2 KINASE | Celgene Corporation (US) | 2025-12-17 | — | — | EP | disclosed |
| EP-3321268-B1 | BICYCLIC HETEROARYL DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF | AGENCY SCIENCE TECH & RES (SG) | 2025-06-04 | — | — | EP | disclosed |
| CN-120058751-A | Pleuromutilin derivative with arylboronic acid or arylboronic acid ester fragment, and preparation method and application thereof | 中国医学科学院药物研究所 | 2025-05-30 | — | — | CN | disclosed |
| US-20250122226-A1 | GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES | NOVO NORDISK AS (DK) | 2025-04-17 | — | — | US | disclosed |
| US-20110224190-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | INCYTE CORPORATION | 2011-09-15 | — | — | US | disclosed |
| WO-2011112662-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | INCYTE CORPORATION (US) | 2011-09-15 | — | — | WO | disclosed |
| WO-2010147776-A1 | SUBSTITUTED -1,3,8-TRIAZASPIRO[4.5]DECANE-2,4-DIONES | MERCK SHARP & DOHME CORP. (US) | 2010-12-23 | — | — | WO | disclosed |
| US-7417169-B2 | Amino alcohol derivatives, medicinal composition containing the same, and use of these | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-08-26 | — | — | US | disclosed |
| US-20070078184-A1 | Amino alcohol derivatives, medicinal composition containing the same, and use of these | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-04-05 | — | — | US | disclosed |
| EP-1679304-A1 | AMINO ALCOHOL DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND USE OF THESE | Kissei Pharmaceutical Co., Ltd. (JP) | 2006-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122226-A1 | GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES | ALB, DBI, FABP4 | LMNA 4627/4885RAB9A 2780/4885MAPK1 2110/4885 |
| US-20070078184-A1 | Amino alcohol derivatives, medicinal composition containing the same, and use of these | ADRB2, ADRA2A, ADRA1A | LMNA 3859/4885RAB9A 577/4885MAPK1 2271/4885 |
| US-12624028-B2 | 1H-pyrazolo[4,3-G]isoquinoline and 1H-pyrazolo[4,3-g]quinoline derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD) | SERPINA2, SERPINC1, SERPINH1 | LMNA 1331/4885RAB9A 3455/4885MAPK1 2379/4885 |
| US-20110224190-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | JAK1, JAK2, JAK3 | LMNA 4748/4885RAB9A 708/4885MAPK1 128/4885 |
| US-20260109708-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS DEGRADERS OF MK2 KINASE | PSME2, MKRN3, RPS6KA2 | LMNA 4171/4885RAB9A 3583/4885MAPK1 637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.